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The  goals  of  cancer  therapy  are  easy  to 
  summarize:  to  identify  patients  at  the 
earliest stage possible of the disease and 
to eradicate tumors without altering the 
overall  health  condition  of  the  patients. 
The  identification  of  cancer  biomark-
ers  and  tumor-selective  drugs  therefore 
represent obvious challenges for the next 
decades. In the genomics and proteomics 
era, the temptation is thus enormous to 
claim that the detection of oncogenes or 
oncoproteins participating in the progres-
sion of a given cancer represents the main 
avenue to diagnose the disease at early stages 
and to subsequently target these genes or 
proteins in order to block tumor growth. 
However, although the last 30 years have 
been rich in grasping information about 
genetic features distinguishing cancer cells 
from normal cells through the identification 
of oncogenes and tumor suppressor genes 
(Hahn and Weinberg, 2002), the translation 
of this information in new drugs is limited 
to very few examples. Worse yet, old demons 
of conventional chemotherapy, namely tox-
icity and resistance, are now dampening 
the original enthusiasm (Force et al., 2007; 
Knight et al., 2010).
Imatinib/Gleevec,  as  an  inhibitor  of 
the bcr-abl fusion protein (Druker et al., 
2001)  and  trastuzumab/Herceptin  as 
inhibitor of the human epidermal growth 
factor receptor 2 (HER2) (Baselga et al., 
1998) are two of the very first examples of 
the development of molecularly targeted 
therapies.  These  drugs  have  represented 
breakthroughs in the treatment of chronic 
myelogenous leukemia (CML) and breast 
cancers,  respectively.  The  identification 
of patients who may benefit from these 
treatments  was  guided  by  the  detection 
of corresponding genetic alterations: the 
Philadelphia  chromosome  consistently 
found in CML patients, formed by a recip-
rocal translocation of DNA leading to a 
fusion gene between cABL (chromosome 
9) and BCR (chromosome 22) (Bartram 
et  al.,  1983),  and  the  overexpression  of 
HER-2/neu as observed in 20–25% inva-
sive breast cancers (Slamon et al., 1987). No 
doubt that these drugs administered to the 
right population of patients have increased 
response rates and survival. Still, we know 
today that the disease can find a way to 
advance  despite  the  treatments:  patients 
with BCR-ABL or HER2-positive cancers 
can still progress after receiving the above 
targeting drugs (often despite encourag-
ing first responses). Potential mechanisms 
of resistance to oncogene-targeting drugs 
include bypass mechanisms and mutations 
of the targets (Gorre et al., 2001; Jones and 
Buzdar, 2009). In addition, potentially fatal 
cardiac toxicity is reported with trastuzu-
mab (Telli et al., 2007) and although better 
tolerated, hematological (neutropenia), and 
non-hematological  (skin  rashes,  edema, 
muscle cramps) toxicities are reported with 
imatinib (Deininger et al., 2005).
The responses to these frustrating obser-
vations may be of two kinds. The obvi-
ous one is to understand the reasons for 
the heterogeneity in responses to a given 
drug, i.e., between patients but also for a 
given patient, between the early beneficial 
phases of a treatment and the late devel-
opment of resistance. This should lead to 
rapid results with the apparition of second 
and third generations of drugs. Some are 
already  making  their  way  to  the  clinics. 
Drugs such as nilotinib and so-called ABL 
allosteric inhibitors may now for instance 
overcome resistance caused by some BCR-
ABL mutations responsible for relapse after 
initial imatinib treatment (Weisberg et al., 
2007; Zhang et al., 2010). This better under-
standing should also stimulate the search 
for new predictive biomarkers to tailor the 
treatment to a patient’s individual genetic 
profile (for review, see Hanash et al., 2008; 
Sawyers, 2008). The need in this matter is 
so acute that there is an increasing consen-
sus to integrate promising biomarkers, even 
if not clinically qualified, into early phase 
trials as exploratory and intermediary end-
points (Yap et al., 2010).
The second and non-exclusive option to 
tackle the limited amounts of safe and effi-
cient drugs issued from our genetic knowl-
edge  of  cancers  is  to  identify  additional 
filter(s) which should be implemented to 
select for better anticancer drugs. It is now 
clear that in vitro activity is not the bot-
tleneck to the development of such drugs 
considering the huge amounts of cytotoxic 
compounds  which  have  been  identified 
along  the  years.  Experimental  and  pre-
clinical in vivo activity should however not 
either be considered as the ultimate filter 
before  clinical  evaluation.  Indeed,  many 
studies using animal models of cancer do 
report the identification of a critical path-
way exquisitely responding to a therapeu-
tic modality based on tumor growth delay 
measurements  or  Kaplan–Meier  survival 
curves. These read-outs clearly underesti-
mate the complexity of signaling networks 
that in fine determine the clinical response 
to a treatment. Instead, the bottleneck to the 
development of better anticancer drugs lies 
in their therapeutic window, i.e., the range 
between the dosage that gives an anti-  tumor 
effect  and  the  amounts  that  give  more 
adverse  effects  than  desired  effects.  The 
new therapeutic strategies based on target-
ing antibodies or small molecules are cer-
tainly a first step in this direction. However, 
although examples as such described above 
are the proof that “intelligent” drugs may 
be designed, the next step is probably to 
identify the best target for this new genera-
tion of molecularly targeted drugs. In other 
words, we need to understand more about 
the molecular networks that control cancer 
cell biology and behavior in order to iden-
tify the nodes in the signaling circuitry of 
tumor cells, which are the most critical in 
driving cancer progression.
If  one  considers  that  a  genetic  defect 
related to the loss of a tumor suppressor gene 
is pharmacologically difficult to correct, the 
Holy Grail would consist in the identification 
of activated oncogenes acting as “vital” nodes 
in the signaling network of cancer cells. The Feron  Targeting cancer addictions
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main source of energy in tumors, even in the 
presence of oxygen, a phenomenon called 
the  Warburg  effect  (Feron,  2009).  Today, 
although we know that lactate and glutamine 
are  also  critical  substrates  for  tumor  cell 
metabolism  (De  Bereradinis  et  al,  2008; 
Sonveaux et al, 2008; Feron, 2009), glyco-
lysis or more exactly glucose to lactate oxi-
dation remains a hallmark of many cancers. 
Interestingly, this upregulation of glycolysis 
is thought to find its origin in an adapta-
tion  to  environmental  constraints  during 
carcinogenesis, in particular the advantage 
to favor local acidosis to harm adjacent cell 
populations and thereby promote tumor cell 
survival (Gillies and Gatenby, 2007; Gatenby 
and Gillies, 2008). Another consequence is 
also a higher capacity to degrade extracellu-
lar matrix and thereby to stimulate invasive-
ness. The Warburg observation can today be 
interpreted as follows: the glycolytic prefer-
ence provides such surviving advantages that 
clonal selection of tumor cells with mutations 
or epigenetic changes will always privilege this 
metabolic pathway even though supporting 
oncogenes and tumor suppressor genes may 
differ (Gillies et al., 2008). Although one view 
is that it continues to confer a proliferative 
advantage even to fully transformed cells, 
another possibility, yet non-exclusive, is to 
consider that tumors cells actually became 
addicted to this metabolic preference at the 
time of pre-malignant lesions or at least at 
early  stages  of  the  disease. Various  drugs 
aiming to block key metabolic pathways in 
tumors are under development (see Tennant 
et al., 2010 for review) and offer the theoreti-
cal advantage to target early lesions as well as 
more aggressive cancers.
As a conclusion, I want to stress that 
the choice was deliberate to not use words 
such as angiogenesis or immunity in this 
Grand  Challenge  and  to  stay  focus  on 
the tumor cells themselves. This is by no 
means a denegation of the relevance of the 
strategies targeting these pathways, neither 
of other conventional treatments such as 
radiotherapy.  These  modalities  represent 
perfect complementary approaches to block 
or reduce the tumor burden. The thera-
peutic  effects  resulting  from  these  other 
approaches are however also a question of 
addiction. For instance, the extent of the 
dependency on angiogenic vessels or the 
influence  of  immunosuppressive  tumor-
associated  macrophages  will  determine 
whether drugs targeting these pathways lead 
efficacy of specific drugs. A good example is 
the efficacy of poly-ADP-ribose polymerase 
(PARP) inhibitors in BRCA-deficient tumors 
(Bryant et al., 2005; Farmer et al., 2005; Fong 
et al., 2009). BRCA genes are classical tumor 
suppressor genes: a defect in homologous 
recombination and associated defect in DNA 
repair are observed in cancer patients carry-
ing germline BRCA gene mutations. While in 
healthy tissues, BRCA proteins may compen-
sate for the PARP-driven inhibition of single 
stranded DNA break repair, such buffering 
is  lost  in  BRCA-mutated  tumors.  Other 
examples of addiction dependent on tumor 
suppressor genes are the loss of PTEN and 
pRB, which lead to the stimulation of PI3K/
mTOR (Neshat et al., 2001) and E2F (Sellers 
and Kaelin, 1997), respectively. Those defects 
consequently render tumor cells particularly 
sensitive to mTOR inhibitors and etoposide 
(which inhibits E2F-activated topoisomerase 
II).
Characterization of addictions other than 
those directly driven by oncogenes certainly 
represents alternative avenues for molecu-
larly targeted compounds. Proteasome and 
heat  shock  protein  inhibitors  are  exam-
ples of drugs which exploit synthetically 
lethal interactions although acting on tar-
gets which are themselves not oncogenic. 
Indeed, the imbalance in the stoichiometry 
of protein complex subunits resulting from 
dysregulated gene and protein synthesis is 
known to lead to protein misfolding and 
associated proteotoxic stress in tumor cells. 
Upregulation of chaperone proteins such 
as hsp90 is one kind of response to cope 
with the exacerbated need for correct fold-
ing (Whitesell and Lindquist, 2005) while 
elimination of excess unfolded or misfolded 
proteins by the proteasome is another one 
(Richardson et al., 2006). Interfering with 
either adaptation will thus lead to stress 
overload which will be more easily reached 
in tumor cells than in normal cells, thereby 
making strategies targeting folding addiction 
particularly safe and efficient.
One other exciting area of investigation is 
nowadays related to what could be coined as 
metabolism addiction. This concept is derived 
from the initial observation by Otto Warburg 
more than 50 years ago according to which 
proliferating  tumor  cells  do  not  exploit 
the  full  capacity  of  oxidative  metabolism 
of glucose to produce avidly needed ATP 
(Warburg, 1956). This observation further 
led to the conclusion that glycolysis is the 
blockade or the silencing of the   expression 
of protein encoded by such an oncogene to 
which cancer cells are addicted (Weinstein, 
2002; Weinstein and Joe, 2008; Luo et al., 
2009), should logically lead to tumor cell 
death. Addiction mostly arises from the loss 
of collateral signaling pathways that renders 
survival of the tumor cell strictly dependent 
on the activity of a given oncogene (Kamb, 
2003). Such dependence largely explains the 
success of imatinib for CML or gastrointes-
tinal stromal tumor (GIST) wherein driving 
oncogenes are BCR-ABL and cKIT, respec-
tively. It is noteworthy that the identifica-
tion of addicting oncogenes may require a 
careful dissection of the signaling circuitry 
in tumor cells. Such oncogene may indeed 
result from a mutation which was neutral 
for the mutations that preceded them but 
is absolutely required for mutations occur-
ring later. Also, it may correspond to one 
of the numerous low-frequency mutations 
occurring during malignancy progression 
and probably largely underestimated so far 
(Greenman et al., 2007).
The  above  considerations  support  the 
concept of synthetic lethality initially used in 
yeast and fly genetic studies and more recently 
introduced in the field of anticancer treat-
ments (Kaelin, 2005). Two genes are said syn-
thetic lethal if mutation of either gene alone 
is compatible with viability but mutation of 
both leads to death. Inhibiting the products of 
genes that are synthetic lethal should by defi-
nition kill cells that harbor such mutations, 
while sparing normal cells. This concept may 
inspire different thoughts or scenarios. First, 
a combination of two molecularly targeted 
agents fulfilling the task of inhibiting syn-
thetically lethal genes or the corresponding 
proteins has more chance to lead to a safe 
cancer cure than any other combination of 
drugs, even if active on apparently distinct 
targets. This is particularly attractive for path-
ways that are activated early during carcino-
genesis since more likely to be synthetically 
lethal with one of the consecutive mutation 
in the malignant cell transformation process. 
Second, pharmacological inhibition of one 
gene synthetically lethal with another gene 
mutated in tumor cells should also selectively 
kill cancer cells (the wild-type form of the 
later gene protecting normal cells). Third, and 
probably most interestingly, the concept may 
be extended to tumor suppressor genes which 
although generally described as undruggable, 
may indirectly participate in promoting the www.frontiersin.org  September 2010  | Volume 1  | Article 120  |  3
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of interest of scientists working on tumor 
biology or anticancer drug discovery, the 
focus should be placed on any forms of 
tumor addictions if one wishes to propose 
therapies with a higher potential to cure 
either to a time- and tumor area-limited 
effect, a shift from a progressive to a stable 
disease, or a clinical response really impact-
ing the overall survival of cancer patients. 
The message is thus that whatever the field 